The global interleukin inhibitors market has emerged as one of the most dynamic segments in the biopharmaceutical industry, catering to the growing need for targeted treatments for chronic and autoimmune diseases. According to Kings Research, the market was valued at USD 20.87 billion in 2023 and is projected to rise to USD 22.11 billion in 2024, eventually...
English
العربية
Français
Español
Português
Deutsch
Nederlands
Italiano
Русский
Română
Português
Ελληνικά
Tiếng Việt